City of Hope | Strategic Alliance Partners

Latest from City of Hope

Noncovalent BTK Inhibitors, CAR T-Cell Therapy Generate Excitement in CLL

September 09, 2021

Article

Sitting at the forefront of clinical development, pirtobrutinib and lisocabtagene maraleucel have generated significant enthusiasm in chronic lymphocytic leukemia.

Dr. Danilov on the Utility of BTK Inhibitors in CLL

September 08, 2021

Video

Alexey V. Danilov, MD, PhD, discusses the utility of BTK inhibitors as a treatment option for patients with chronic lymphocytic leukemia.

Dr. Herrera on the Utility of CAR T-Cell Therapy in Hematologic Cancers

September 03, 2021

Video

Alex Herrera, MD, discusses the utility of CAR T cells in patients with hematologic cancers.

Untangling Fact From Bias in the Age of Social Media and Mistrust

September 02, 2021

Article

It is difficult to overstate the confusion associated with our nation’s messaging regarding a well-considered, rational, and scientifically based public health–focused approach to the current and future ramifications of the COVID-19 pandemic.

Dr. Garg on the Need for Novel Imaging Techniques in nmCRPC

September 01, 2021

Video

Natasha Garg, DO, discusses the utility of novel imaging techniques in patients with nonmetastatic castration-resistant prostate cancer.

Dr. Lyou on Key Takeaways from the ENZAMET Trial in Metastatic Prostate Cancer

August 31, 2021

Video

Yung Lyou, MD, PhD, discusses the key takeaways from the phase 3 ENZAMET trial in metastatic prostate cancer.

Dr. Dorff on Biomarkers of Response to PARP Inhibitors in Prostate Cancer

August 30, 2021

Video

Tanya B. Dorff, MD, discusses biomarkers of response to PARP inhibitors under investigation in prostate cancer.

Dr. Lyou on the Efficacy of ADT Plus Docetaxel in High-Volume mHSPC

August 30, 2021

Video

Yung Lyou, MD, PhD, discusses the efficacy of androgen-deprivation therapy plus docetaxel in patients with metastatic hormone-sensitive prostate cancer.

Dr. Garg on the Emergence of Antiandrogen Agents in nmCRPC

August 25, 2021

Video

Natasha Garg, DO, discusses the emergence of antiandrogen agents in the nonmetastatic castration-resistant prostate cancer treatment paradigm.

Dr. Burnham on Correlations Between Race and HER2 Positivity in Prostate Cancer

August 24, 2021

Video

Leanne Burnham, PhD, discusses the correlation between HER2 positivity and race in patients with prostate cancer.

Dr. Fakih on Efficacy With Regorafenib Plus Nivolumab in Metastatic CRC

August 23, 2021

Video

Marwan Fakih, MD, discusses efficacy reported with regorafenib plus nivolumab in patients with mismatch repair–proficient and microsatellite stable metastatic colorectal cancer.

Krie and Yuan Talk Toxicity Management in Breast Cancer

August 23, 2021

Podcast

Dr. Krie and Dr. Yuan discussed treatment-related adverse effects one should be aware of and prepared to manage, recommended management strategies for these TRAEs, and important points to emphasize to patients before they begin treatment.

Zandelisib/Zanubrutinib Produces Promising Safety, Efficacy in Relapsed/Refractory B-Cell Malignancies

August 18, 2021

Article

Alexey V. Danilov, MD, discusses the safety and efficacy achieved with the novel combination comprised of zandelisib and zanubrutinib in patients with relapsed/refractory B-cell malignancies.

City of Hope Expands Its Southern California Presence With Addition of Pacific Shores Medical Group

August 09, 2021

Article

City of Hope, a world-renowned cancer research and treatment center, today announced that acclaimed Pacific Shores Medical Group has joined City of Hope.

Pal Provides Perspective on Pivotal Trials in RCC and Prostate Cancer

July 27, 2021

Article

Insights generated from several trials presented during the 2021 ASCO Annual Meeting in renal cell carcinoma illustrate the importance of evaluating checkpoint inhibitors in earlier stages of disease, quality of life, and long-term outcomes, and other data that point to 2 potential new standards of care in prostate cancer.

Siddiqi Spotlights Latest Data on Optimization of Therapy in Hematologic Malignancies

July 23, 2021

Article

Data presented during the 2021 ASCO Annual Meeting offered insight into the optimization of BTK inhibitors, induction therapy, consolidative therapy, and radiation therapy for patients across the paradigm of hematologic malignancies.